Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Achieve Life Sciences (ACHV) EBIAT (2016 - 2026)

Achieve Life Sciences (ACHV) has disclosed EBIAT for 17 consecutive years, with -$10.2 million as the latest value for Q1 2026.

  • Quarterly EBIAT rose 20.48% to -$10.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$52.0 million through Mar 2026, down 12.78% year-over-year, with the annual reading at -$54.6 million for FY2025, 37.21% down from the prior year.
  • EBIAT for Q1 2026 was -$10.2 million at Achieve Life Sciences, up from -$14.7 million in the prior quarter.
  • The five-year high for EBIAT was -$5.5 million in Q4 2023, with the low at -$14.7 million in Q4 2025.
  • Average EBIAT over 5 years is -$10.4 million, with a median of -$10.5 million recorded in 2022.
  • The sharpest move saw EBIAT soared 51.25% in 2023, then crashed 125.11% in 2024.
  • Achieve Life Sciences' EBIAT stood at -$11.2 million in 2022, then soared by 51.25% to -$5.5 million in 2023, then plummeted by 125.11% to -$12.3 million in 2024, then decreased by 18.94% to -$14.7 million in 2025, then soared by 30.43% to -$10.2 million in 2026.
  • Per Business Quant, the three most recent readings for ACHV's EBIAT are -$10.2 million (Q1 2026), -$14.7 million (Q4 2025), and -$14.4 million (Q3 2025).